Superbugs and Superdrugs - A Focus on Antibacterials

Date: 04-Mar-13 to 06-Mar-13
Location: Copthorne Tara Hotel / London / United Kingdom
Category: Chemicals Healthcare & Pharmaceuticals Science Conferences & Trade Fairs

SMi is proud to present their 15th Annual Superbugs and Superdrugs conference.
This unique event will bring together industry leaders from big pharma, biotechs, regulatory agencies and academia to discuss the latest in the antibacterial market. The conference will present attendees with a complete view into the latest in combating multi-drug resistance, diagnostics and new focus on vaccine development for the prevention of nosocomial bacterial infections. Also it will address the latest developments in natural product advancements and strategies to building public-private partnerships to overcome antibacterial resistance.
With senior industry representatives presenting on their own experiences and referring to case studies, success stories and failures, this event promises to be a unique forum for problem-solving debate and idea-sharing discussion.

Key Topics for 2013 will include:
• The EMA approach to regulating antimircobials
• Case Studies on mechanisms of action for inhibiting
• Strategies for combating bacterial genetic variations influences of infections
• Current partnerships addressing antimicrobial resistance
• Utility of natural products and alternative approaches to aid drug
For more information visit http://www.smi-online.co.uk/goto/superbugssuperdrugs2.asp
Or contact Fateja Begum on +44 0207 827 6184 or email fbegum@smi-online.co.uk

Visitors

• Chief Scientific Officers
• Senior Vice Presidents
• Chief Medical Officers
• Research Scientists
• Clinical Microbiologists
• R&D Project Managers • Heads of Anti-Infectives Discovery
• Clinical Trials Managers
• Principal Scientists
• Senior Vice Presidents of R&D
• Business Development Managers
• Product Managers

Exhibitors

Affinium Pharmaceuticals; Anacor Pharmaceuticals Inc; Aquapharm Biodiscovery; Aquapharm Bio-Discovery Ltd; Astellas Pharma Europe; Aurasense Therapeutics; Basilea Pharmaceutica Ltd; Biota; Boehringer Ingelheim; Cantab Biopharmaceuticals Ltd; Center For Anti-Infective Agents; Cerexa, Inc.; Creative Antibiotics; Cubist Pharmaceuticals; Da Volterra; Destiny Pharma; Euprotec; European Commision; Evolva SA; Genentech; GlaxoSmithKline; Health Protection Agency; Imperial College London; KWS Biotest; LL Silver Consulting; London School Of Economics; Meiji Seika Kaisha Ltd, Pharmaceutical Division; Merck Research Lab; Merck Research Laboratories; MorphoSys AG; MRC Human Nutrition Research; Northwestern University; Nosopharm; Novartis; Novartis Institutes for Biomedical Research Inc.; Novartis Pharma; Oxford University Clinical Research Unit; Pfizer Antibacterials RU; Pfizer Global Research and Development,; Procarta Biosystems Ltd.; Quotient Bioresearch; Quotient Bioresearch Ltd.; Rib-X Pharmaceuticals; Rinat-Pfizer; Selcia; St George's, University of London; Summit; Tiber Creek Partners; TranScrip Partners; Unilever Ltd; Unilever Ventures; University of Manchester School of Translational Medicine; Vertex Pharmaceuticals; Vivexia;

Go to event website